^
Association details:
| Biomarker: | ER negative + PIK3CA H1047R |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Tukysa (tucatinib) (HER2 inhibitor) + OKI-219 (PI3Kα H1047R mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OKI-219, a PI3KαH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in pre-clinical PI3KαH1047R mutant breast cancer models.
Published date:
12/02/2023
Excerpt:
Dosing OKI-219 in combination with HER2-inhibitors, such as tucatinib, led to tumor regressions in the ER HER2+ and H1047R mutant breast cancer CDX model HCC1954, also at doses where no regressions were observed with single agent treatment.
